低分子肝素治疗进展性脑梗死临床疗效观察

Clinical therapeutic effect of low molecular weight heparin treatment for progressive stroke

目的探讨应用低分子肝素治疗进展性脑梗死(PCI)的临床疗效。方法将124例进展性脑梗死患者随机分为治疗组与对照组,两组均进行基础治疗。治疗组加用低分子肝素钙5 000U腹部皮下注射,每日2次,共14d。比较两组治疗前后神经功能缺损程度及临床疗效。结果两组治疗7d和14d后神经功能缺损程度评分改善情况及临床疗效,治疗组优于对照组,差异有统计学意义(P<0.05)。治疗组治疗前后血小板计数、凝血酶原时间、部分凝血活酶差异无统计学意义,两组均无明显不良反应发生。结论低分子肝素治疗进展性脑梗死临床疗效佳,不良反应小,值得临床广泛推广应用。

Objective To discuss the clinical therapeutic effect of low molecular weight heparin treatment for progressive stroke.Methods 124 progressive stroke patients were randomly divided into treatment group and control group,treatment group was treated with low molecular weight heparin 5 000 U and basic treatment,2 times one day,a total of 14 d,while control group received basic treatment.The degree of neurological deficit and clinical efficacy in the two groups were compared before and after treatment.Results The score of neurological deficits and clinical efficacy of the two groups was decreased after treatment with 7 and 14 d,especially the treatment group,the difference was statistically significant（P0.05）.Platelet count,prothrombin time and active partial thromboplastin time were no statistical significance between before and after treatment in treatment group,there were no significant adverse reaction in two groups.Conclusion Low molecular weight heparin treatment the progressive stroke could be get Significant effect,and small adverse reaction,which be worthy of clinical generalization and applicaton.